# AZD9291 First Time In Patients Ascending Dose Study

> **NCT01802632** · PHASE1,PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 603 (actual)

## Conditions studied

- Advanced Non Small Cell Lung Cancer
- Advanced (Inoperable) Non Small Cell Lung Cancer

## Interventions

- **DRUG:** AZD9291

## Key facts

- **NCT ID:** NCT01802632
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-04
- **Primary completion:** 2015-05-01
- **Final completion:** 2023-12-11
- **Target enrollment:** 603 (ACTUAL)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01802632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01802632, "AZD9291 First Time In Patients Ascending Dose Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01802632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*